Abstract 571P
Background
Brain metastases (BM) are common among EGFRm NSCLC patients. And it has been associated with treatment failure and limited survival especially patients with multiple BMs. Dacomitinib is a selective, irreversible, Pan-HER TKI. It brought significant PFS and OS improvement compared with Gefitinib in phase 3 randomize study ARCHER 1050. However, patients with BM or leptomeningeal metastases were excluded in this study. We hereby conducted this phase II study (NCT02047747) to prospectively evaluate the efficacy and safety of Dacomitinib in NSCLC patients with multiple BMs and here are initial results of this study.
Methods
Treatment-naive stage IIIB/IV EGFR-mutant NSCLC patients with multiple and measurable BMs(≥ 3 metastatic lesions in the brain and at least 1 target lesion’s diameter among these lesions should be ≥1 cm) received Dacomitinib45mg orally once daily. Assessments were performed every8 weeks until disease progression (PD) as per RECIST v1.1. End points included PFS, intracranial ORR (iORR), ORR, and safety.
Results
At data cut-off (Jul 1, 2023), a total of 14 patients were enrolled and the median follow-up time was 24 months (range, 4-28m), of which 10 patients had measurable CNS response. For all patients, the mPFS was 15.3m(8/14),ORR was 78.6% while DCR was 100%.The iORR was 80% and iDCR was 100%. The mPFS in patients with 19Del (8/14,57.1%) and21L858R (6/14,42.9%) are 15.3 and 15.2m, ORR are 87.5% and 66.7%, respectively. There are no new adverse events (AEs) compared to ARCHER1050.The most common AEs were rash (10/14; 71.4%), diarrhea (8/14; 57.1%), paronychia (3/14; 21.4%). Temporary discontinuations and dose modification occurred in 2 (14.3%) and 1 (7.1%) patient, respectively.
Conclusions
Dacomitinib showed promising intracranial antitumor activity with a manageable safety profile as first-line therapy in EGFR-mutant NSCLC patients with multiple brain metastases.
Clinical trial identification
NCT02047747.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Funding
Pfizer.
Disclosure
Y. Yu: Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Rohce, MSD. Y. Pan: Financial Interests, Personal, Advisory Board: Pfizer, AstraZeneca, Roche, MSD; Financial Interests, Personal, Invited Speaker: Pfizer. J. Zhou: Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Roche, MSD. S. Lu: Financial Interests, Institutional, Invited Speaker: Hansoh, AstraZeneca, Roche, Hengrui; Financial Interests, Institutional, Advisory Board: AstraZeneca, Prizer, Boehringer Ingelheim, Hutchison MediPharma, ZaiLab, GenomiCare, Yuhan Corporation, Menarini, InventisBio Co.Ltd, Roche, Simcere Zaiming Pharmaceutical Co., Ltd.; Financial Interests, Personal, Research Grant: AstraZeneca, Hutchison, BMS, Heng Rui, Roche, Hansoh, BeiGene, Lilly Suzhou Pharmaceutical Co.Ltd; Financial Interests, Personal, Coordinating PI: FibroGen.
Resources from the same session
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract